Johnson & Johnson (JNJ) said Monday that new data from a phase 3 study of Tremfya, or guselkumab, showed its sustained clinical and endoscopic efficacy through week 92 in adults with moderately to severely active ulcerative colitis.
The company said 72% of patients treated with Tremfya were in clinical remission, with nearly all of them staying off steroid treatment for two months or longer, and 43% achieved endoscopic remission.
Among those who improved by week 44, 84% retained that progress through week 92, Johnson & Johnson said.
The outcomes were consistent regardless of prior exposure to biologic drugs or JAK inhibitors, according to the company.
No new safety issues were identified, and the drug's risk profile remained consistent with previous findings, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。